Effects of pralatrexate injection: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of pralatrexate injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of pralatrexate injection: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of pralatrexate injection: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Pralatrexate is a folate antagonist that selectively enters cells expressing reduced folate carrier type 1 (RFC-1) and competitively inhibits dihydrofolate reductase (DHFR), leading to interruption of RNA synthesis, DNA replication, and apoptosis. 12 . It has shown promise in treating cancers such as relapsed or refractory peripheral T-cell lymphoma (PTCL). 13 . A Phase 1 trial found that pralatrexate, combined with a CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), was a safe and effective treatment option for patients with newly diagnosed PTCL, warranting further investigation. 10 . A meta-analysis found pralatrexate to be safer than the human diploid cell vaccine (HDCV) for rabies. 9 . Pralatrexate also has the potential to promote cartilage formation and assist in cartilage repair. 11 . However, studies in dogs have shown potential sex-dependent non-specific effects of pralatrexate, with an increased risk of all-cause mortality in females and a reduced risk of death in males. 6 . These non-specific effects can be more pronounced in dogs when both mothers and offspring receive rabies vaccinations. 7 . Rabies vaccination did not provide protection against mild self-reported illnesses in a group of young and healthy adults attending veterinary school. 8 . Pralatrexate has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. 13 .

Benefits and Risks

Benefits Summary

Pralatrexate has proven effective in treating relapsed or refractory peripheral T-cell lymphoma. 13 . Combined with a CHOP regimen, pralatrexate has shown promise as a safe and effective treatment option for patients with newly diagnosed PTCL. 10 . Pralatrexate has been found to be a safer rabies vaccine than the human diploid cell vaccine (HDCV). 9 . Pralatrexate demonstrates potential to promote cartilage formation and aid in cartilage repair. 11 .

Risks Summary

Pralatrexate may cause side effects such as anemia, neutropenia, febrile neutropenia, fatigue, mucosal inflammation, nausea, and vomiting. 10 . It may also have sex-dependent non-specific effects in dogs, leading to an increased risk of all-cause mortality in females and a reduced risk of death in males. 6 . These non-specific effects can be more pronounced in dogs when both mothers and offspring receive rabies vaccinations. 7 .

Comparison of Studies

Similarities

Multiple studies indicate that pralatrexate is a beneficial treatment option for relapsed or refractory peripheral T-cell lymphoma. 13 10 . Research also points to pralatrexate being a safer rabies vaccine than the human diploid cell vaccine (HDCV). 9 .

Differences

Research shows potential sex-dependent non-specific effects of pralatrexate in dogs, with an increased risk of all-cause mortality in females and a reduced risk of death in males. 6 . These non-specific effects can be more pronounced in dogs when both mothers and offspring receive rabies vaccinations. 7 . Rabies vaccination did not provide protection against mild self-reported illnesses in a group of young and healthy adults attending veterinary school. 8 .

Consistency and Inconsistencies

Numerous studies indicate that pralatrexate is an effective treatment option for relapsed or refractory peripheral T-cell lymphoma. 13 10 . However, research also points to potential sex-dependent non-specific effects in dogs, with an increased risk of all-cause mortality in females and a reduced risk of death in males. 6 7 . These effects can be more pronounced when both mothers and offspring receive rabies vaccinations. 7 . Rabies vaccination did not provide protection against mild self-reported illnesses in a group of young and healthy adults attending veterinary school. 8 . These findings may contain conflicting information about the safety and efficacy of pralatrexate.

Considerations for Real-World Application

Pralatrexate has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. 13 . However, it is essential to consider the potential sex-dependent non-specific effects in dogs, as well as the increased potential for these effects when both mothers and offspring receive rabies vaccinations. 6 7 . Caution should be exercised when using pralatrexate in light of these side effects.

Limitations of Current Research

Research on the non-specific effects of pralatrexate is limited. Studies have shown that these effects can be more pronounced in dogs when both mothers and offspring receive rabies vaccinations. 7 . Further research is needed to gain a better understanding of these non-specific effects. Additional studies on potential uses for pralatrexate are also warranted.

Future Research Directions

Further research is required to investigate the non-specific effects of pralatrexate. Studies should focus on the non-specific effects of pralatrexate in dogs, particularly the potential for more pronounced effects when mothers and offspring receive rabies vaccinations, and investigate methods to mitigate these effects. Additional research into other potential applications for pralatrexate is also necessary.

Conclusion

Pralatrexate has shown promise as an effective treatment for relapsed or refractory peripheral T-cell lymphoma. 13 10 . Pralatrexate has been found to be a safer rabies vaccine than the human diploid cell vaccine (HDCV). 9 . Pralatrexate demonstrates potential to promote cartilage formation and aid in cartilage repair. 11 . However, studies have shown potential sex-dependent non-specific effects in dogs, with an increased risk of all-cause mortality in females and a reduced risk of death in males. 6 . These non-specific effects can be more pronounced when both mothers and offspring receive rabies vaccinations. 7 . When using pralatrexate, it is important to consider these potential side effects.

Literature analysis of 13 papers
Positive Content
11
Neutral Content
2
Negative Content
0
Article Type
8
1
1
2
13
1.

[Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value].

Author: HacibektaşoğluA, InalA, EyigünC, BarutA, TürkayF A

Rabies prophylaxis
Fever
Local pain
Lymphadenopathy

PVRV and HDCV vaccines for rabies were equally effective in inducing neutralizing antibodies in healthy male volunteers. Both vaccines provided a year-long protection until the first booster dose.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : Turkish

2.

Immunoenhancement with combined rabies and aluminium-adjuvanted tetanus vaccines.

Author: PhanuphakP, KhaoplodP, SriwanthanaB, PhanpanichT, WonguraiS, RoumiantzeffM

immunoenhancement
vaccine efficacy increase

Combining tetanus toxoid with purified Vero cell rabies vaccine (PVRV) in the 2-1-1 regimen significantly increased anti-rabies antibody levels, but only when aluminum hydroxide-adsorbed tetanus toxoid was used. This combination did not affect anti-tetanus antibody levels or increase side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Anti-rabies treatment of dog-bite victims in Lagos, Nigeria: trial of suckling mouse brain and fetal bovine kidney cell rabies vaccines.

Author: HarryT O, AdeigaA, AnyiwoC E, NasidiA

Prevents rabies
Generalized reactions
Local reactions

Suckling mouse brain (SMBV) and fetal bovine kidney (FBKV) rabies vaccines were equally efficacious and well tolerated in dog-bite victims.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV).

Author: LangJ, CetreJ C, PicotN, LantaM, BriantaisP, VitalS, Le MenerV, LutschC, RotivelY

Rabies vaccination
Asthenia

A new chromatographically purified rabies vaccine (CPRV) was found to be as immunogenic as purified Vero cell vaccine (PVRV) and associated with fewer systemic reactions in a randomized, double-blind study.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia.

Author: AyeleW, FekaduM, ZewdieB, BeyeneM, BogaleY, MochaK, EgziabherF G

Rabies prophylaxis

This study assessed the immunogenicity and efficacy of a Fermi-type rabies vaccine in mice and humans. In mice, the vaccine induced protective levels of rabies virus neutralizing antibodies (VNA). Booster doses did not significantly enhance the immune response. In humans, most patients receiving the vaccine had detectable VNA levels by day 14. The study provides the first documentation of the efficacy and immunogenicity of this specific rabies vaccine in both humans and mice.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Sex-differential non-specific effects of rabies vaccine in dogs: An extended analysis of a randomized controlled trial in a high-mortality population.

Author: KnobelDarryn L, AregaSintayehu M, ConanAnne

All-cause mortality

This study found a significant sex-specific effect of non-live rabies vaccination on all-cause mortality in a high-mortality dog population. Primary vaccination increased the hazard of death among females, while a second dose decreased the hazard among males. These findings highlight the importance of considering sex-specific effects when evaluating vaccine efficacy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Non-specific effects of maternal and offspring rabies vaccination on mortality and antibiotic use in a Danish pig herd: A randomized trial.

Author: JensenKristoffer Jarlov, TolstrupLola Kathe, KnobelDarryn L, AabyPeter, JungersenGregers, LarsenLars Erik, KristensenCharlotte Sonne, BennChristine Stabell

Rabies vaccination
Non-specific effects

This study investigated the non-specific effects (NSE) of rabies vaccine in piglets, particularly the potential modifying effect of maternal priming with the vaccine.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.

Author: OditaChristianah I, ConanAnne, Smith-AntonyMarshalette, BatticeJuliet, EnglandShianne, BarryDonna, GessnerBradford D, KnobelDarryn L

This randomized controlled trial investigated whether a rabies vaccine could protect against other common infections. The results showed no significant difference in the incidence of common infections between vaccinated and unvaccinated participants. This suggests that the rabies vaccine does not offer broad protection against other infections.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis.

Author: WangShi-Yuan, SunJin-Fang, LiuPei, LuoLi, LiJing-Xin, ZhuFeng-Cai, ShenXu-Xiang, MengFan-Yue

Rabies prevention
Adverse reactions

Human diploid cell vaccine (HDCV) was found to be safer than purified vero cell vaccine and PCECV in terms of adverse reactions. However, no significant difference was observed in terms of immunogenicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.

Author: HuiJohn, PrzespoEugene, ElefanteAnjana

PTCL treatment
Discontinuation
Dose reduction
Mucositis

Pralatrexate (PDX), a synthetic folate analog antimetabolite, has demonstrated clinical benefit for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PDX achieved durable complete and partial responses in patients who had failed multiple prior treatment regimens.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.

Author: MalikShakun M, LiuKe, QiangXu, SridharaRajeshwari, TangShenghui, McGuinnW David, VerboisS Leigh, MaratheAnshu, WilliamsGene M, BullockJulie, TornoeChristoffer, LinSue Ching, OcheltreeTerrance, VialpandoMilinda, KacubaAlice, JusticeRobert, PazdurRichard

PTCL treatment

Folotyn (pralatrexate injection) was approved by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), the first drug approved for this indication.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.